Advancements in the molecular understanding of major depressive disorder uncovering novel targets with therapeutic promise: focus on recurrence of illness
The future of recurrent MDD therapeutics resides in multi-targeting the ROI-associated pathways with NIMETOX-guided interventions aimed at attenuating immune sensitization, rectifying metabolic dysfunction, reducing oxidative toxicity, and concurrently restoring neuroplasticity. The development of such integrative therapies is an urgent imperative if we are to alter the natural trajectory of recurrent depression.
Authors
- Abbas Firras Almulla (ORCID: https://orcid.org/0000-0002-7667-6731)
- Drozdstoy Stoyanov (ORCID: https://orcid.org/0000-0002-9975-3680)
- Michael H. J. Maes (ORCID: https://orcid.org/0000-0002-2012-871X)
- Yingqian Zhang (ORCID: https://orcid.org/0000-0002-5073-0787)
Institutions
- Academy of Medical Sciences (GB)
- European Union (BE)
- University of Electronic Science and Technology of China (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Medical University Plovdiv (BG)
- King Chulalongkorn Memorial Hospital (TH)
- Iraqi University (IQ)
- Kyung Hee University (KR)
- Islamic University (BD)
- Sichuan Provincial Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Expert Opinion on Therapeutic Targets
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1080/14728222.2025.2608029
- Citations
- 2
- Primary Topic
- Tryptophan and brain disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.16